XENON PHARMACEUTICALS INC (XENE)
CA98420N1050 - Common Stock
XENE Makes Notable Cross Below Critical Moving Average
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024
– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term...
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
Xenon to Showcase New Long-Term Azetukalner Data at AES 2024
Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS and findings around mental...
Xenon to Present at Upcoming Investor Conferences
Xenon to Present at Upcoming Investor Conferences
VANCOUVER, British Columbia and BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused...
Xenon Reports Q3 2024 Financial Results and Business Update
Xenon Reports Q3 2024 Financial Results and Business Update
– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension...
Xenon to Report Q3 2024 Financial Results on November 12, 2024
Xenon to Report Q3 2024 Financial Results on November 12, 2024
VANCOUVER, British Columbia and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused...
XENE Crosses Above Key Moving Average Level
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
VANCOUVER, British Columbia and BOSTON, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused...
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress
Three presentations highlighting long-term data and improved quality of life outcomes in adults with focal onset seizures VANCOUVER, British Columbia and...
Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024.
XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xenon Pharmaceuticals (NASDAQ:XENE) just reported results for the second quarte...
Xenon Reports Q2 2024 Financial Results and Business Update
Xenon Reports Q2 2024 Financial Results and Business Update
— Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025— MDD program on track with Phase 3 study expected to initiate...
Xenon to Report Q2 2024 Financial Results on August 8, 2024
Conference Call and webcast scheduled at 4:30 pm ET
Xenon to Report Q2 2024 Financial Results on August 8, 2024
Conference Call and webcast scheduled at 4:30 pm ET...
XENE Makes Bullish Cross Above Critical Moving Average
Oversold Conditions For Xenon Pharmaceuticals (XENE)
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical...
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company,...
XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024
XENE stock results show that Xenon Pharmaceuticals beat analyst estimates for earnings per share the first quarter of 2024.
XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xenon Pharmaceuticals (NASDAQ:XENE) just reported results for the first quarter...
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful...
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company,...
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company,...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company,...